Physician
Vo Medical Center
Vo Medical Center was paid $14.08M by Medicaid between Jan 2018 and Nov 2024, across 201 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 21% of everything it billed.
33Billing provider infoVO MEDICAL CENTER
EL CENTRO, CA 92243
EL CENTRO, CA 92243
33aNPI1609118041assigned 03/25/2013
33bProvider typeGeneral Practice Physician
28Total paid$14.08M
24GClaims535,870
24DCodes billed201
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Practice Physician providers in California
Rank by total paid#4 of 474
Median peer was paid$10K
This provider vs. median1,358×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,564 | $302K | |
| 2019 | 21,348 | $505K | |
| 2020 | 73,195 | $1.84M | |
| 2021 | 184,391 | $5.31M | |
| 2022 | 177,788 | $4.61M | |
| 2023 | 58,436 | $1.42M | |
| 2024incomplete | 8,148 | $91K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 77,561 | 64,457 | $3.02M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 16% | 66,804 | 55,262 | $2.21M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 14% | 68,623 | 57,445 | $1.95M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.2% | 24,047 | 21,096 | $1.15M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.7% | 19,940 | 16,317 | $805K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 5.5% | 17,224 | 17,150 | $770K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.4% | 55,198 | 45,507 | $616K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.1% | 10,359 | 10,011 | $439K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.3% | 13,765 | 11,583 | $326K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 6,748 | 6,725 | $144K |
| 0002A | <1% | 3,181 | 3,180 | $116K | |
| 0001A | <1% | 3,010 | 3,009 | $113K |
189 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 7,086 | $111K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,026 | $111K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,563 | $99K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,843 | $97K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,938 | $85K |
| 80061 | Lipid panel | <1% | 8,198 | $80K |
| 0011A | <1% | 2,023 | $77K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 621 | $74K |
| 0012A | <1% | 1,886 | $73K | |
| 86769 | <1% | 1,752 | $64K | |
| 80053 | Comprehensive metabolic panel | <1% | 7,761 | $64K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 799 | $61K |
| 82607 | <1% | 5,295 | $60K | |
| 84481 | <1% | 4,182 | $54K | |
| 82728 | <1% | 4,999 | $52K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 728 | $48K |
| 0064A | <1% | 1,203 | $48K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,476 | $47K |
| 84439 | <1% | 6,838 | $46K | |
| 0054A | <1% | 1,138 | $45K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,789 | $44K |
| 86235 | <1% | 375 | $43K | |
| 82746 | <1% | 3,780 | $42K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 398 | $42K |
| 0071A | <1% | 996 | $40K | |
| 84466 | <1% | 4,071 | $39K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 691 | $39K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 514 | $36K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,553 | $31K |
| 83540 | <1% | 5,895 | $29K | |
| 97032 | <1% | 2,746 | $26K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 128 | $25K |
| 83735 | <1% | 4,988 | $25K | |
| 0072A | <1% | 590 | $24K | |
| 82670 | <1% | 1,060 | $23K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,249 | $22K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 470 | $22K |
| 86480 | <1% | 372 | $20K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 630 | $18K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 630 | $18K |
| 83525 | <1% | 2,052 | $18K | |
| 84403 | <1% | 901 | $17K | |
| 84144 | <1% | 1,014 | $16K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 223 | $15K |
| 0004A | <1% | 359 | $14K | |
| 0031A | <1% | 359 | $14K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 468 | $13K |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allowed practitioner development and/or revision of care plans | <1% | 1,733 | $13K |
| 87503 | <1% | 603 | $12K | |
| 84100 | <1% | 3,307 | $12K | |
| 99457 | <1% | 972 | $11K | |
| 83520 | <1% | 361 | $10K | |
| 84153 | <1% | 727 | $9K | |
| 97012 | <1% | 959 | $9K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 249 | $9K |
| 99490 | Ccm add 20min | <1% | 1,748 | $8K |
| 81002 | <1% | 4,226 | $8K | |
| 0003A | <1% | 183 | $7K | |
| 99349 | <1% | 638 | $7K | |
| 93000 | <1% | 384 | $7K | |
| 90688 | <1% | 680 | $7K | |
| 99454 | <1% | 440 | $7K | |
| 76770 | <1% | 100 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 278 | $7K |
| 0124A | <1% | 169 | $7K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 617 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,205 | $6K |
| 0013A | <1% | 144 | $6K | |
| 99384 | <1% | 87 | $6K | |
| 76536 | <1% | 92 | $5K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,665 | $5K |
| 0052A | <1% | 126 | $5K | |
| 0051A | <1% | 127 | $5K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 946 | $5K |
| 96127 | <1% | 1,053 | $5K | |
| 82043 | <1% | 1,134 | $4K | |
| 86140 | <1% | 1,028 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 15 | $4K |
| 86225 | <1% | 346 | $4K | |
| 99223 | Prolong inpt eval add15 m | <1% | 67 | $4K |
| 83001 | <1% | 220 | $4K | |
| 83002 | <1% | 219 | $4K | |
| 86038 | <1% | 352 | $3K | |
| 84550 | <1% | 1,388 | $3K | |
| 77080 | <1% | 114 | $3K | |
| 20610 | <1% | 108 | $3K | |
| 92553 | <1% | 133 | $3K | |
| 86003 | <1% | 23 | $3K | |
| 72100 | <1% | 98 | $3K | |
| 99458 | <1% | 294 | $3K | |
| 86200 | <1% | 375 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 25 | $2K |
| 0134A | <1% | 59 | $2K | |
| 90715 | <1% | 249 | $2K | |
| 83970 | <1% | 56 | $2K | |
| 99439 | <1% | 214 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 19 | $2K |
| 93970 | <1% | 15 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 57 | $2K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 56 | $2K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 109 | $2K |
| 82947 | <1% | 1,165 | $2K | |
| 82977 | <1% | 718 | $1K | |
| 82150 | <1% | 819 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 87 | $1K |
| 11721 | <1% | 116 | $1K | |
| 73030 | <1% | 53 | $1K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 26 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 177 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 53 | $973.35 |
| 90651 | <1% | 144 | $937.01 | |
| 0034A | <1% | 24 | $920.00 | |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 261 | $828.44 |
| 72040 | <1% | 37 | $817.52 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 15 | $728.75 |
| 99306 | Prolong nursin fac eval 15m | <1% | 91 | $652.90 |
| 87905 | <1% | 57 | $594.06 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 296 | $589.94 |
| 90674 | <1% | 42 | $582.28 | |
| 99310 | Prolong nursin fac eval 15m | <1% | 13 | $530.82 |
| 83655 | <1% | 47 | $499.50 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 52 | $493.43 |
| 90734 | <1% | 96 | $450.07 | |
| 94726 | <1% | 12 | $435.60 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 19 | $427.72 |
| 93925 | <1% | 14 | $426.02 | |
| 90686 | <1% | 46 | $417.73 | |
| 94060 | <1% | 12 | $394.05 | |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 565 | $388.58 |
| 84460 | <1% | 529 | $382.30 | |
| 99173 | <1% | 120 | $382.17 | |
| 90710 | <1% | 31 | $365.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 41 | $364.45 |
| 84450 | <1% | 540 | $355.65 | |
| 90619 | <1% | 54 | $351.00 | |
| 72110 | <1% | 14 | $350.80 | |
| 90696 | <1% | 28 | $347.38 | |
| 73560 | <1% | 14 | $318.24 | |
| 82247 | <1% | 515 | $315.42 | |
| 84075 | <1% | 518 | $314.14 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 19 | $297.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 55 | $290.94 |
| 82040 | <1% | 479 | $285.52 | |
| 90633 | <1% | 27 | $283.22 | |
| 11056 | <1% | 12 | $271.77 | |
| 82565 | <1% | 476 | $255.09 | |
| 82310 | <1% | 467 | $252.65 | |
| 84155 | <1% | 482 | $219.19 | |
| 84520 | <1% | 481 | $197.00 | |
| 85018 | <1% | 182 | $166.05 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 96 | $153.47 |
| 84132 | <1% | 417 | $151.29 | |
| 84295 | <1% | 404 | $150.96 | |
| 92551 | <1% | 13 | $143.46 | |
| 86580 | <1% | 41 | $141.04 | |
| 80076 | <1% | 24 | $140.36 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19 | $133.37 |
| 99348 | <1% | 88 | $118.83 | |
| 81001 | <1% | 54 | $117.74 | |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | <1% | 77 | $108.70 |
| 94760 | <1% | 87 | $102.65 | |
| 82570 | <1% | 28 | $89.41 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 75 | $84.16 |
| 99453 | <1% | 37 | $66.60 | |
| 82270 | <1% | 16 | $46.72 | |
| 81025 | <1% | 12 | $36.80 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $34.08 |
| 99000 | <1% | 41 | $33.28 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 28 | $30.00 |
| 82374 | <1% | 15 | $19.04 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13 | $18.67 |
| 93923 | <1% | 13 | $2.37 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 63 | $1.90 |
| 3008F | 0% | 789 | $0.00 | |
| 3074F | 0% | 253 | $0.00 | |
| 3075F | 0% | 14 | $0.00 | |
| 2001F | 0% | 753 | $0.00 | |
| 1170F | 0% | 28 | $0.00 | |
| 3080F | 0% | 16 | $0.00 | |
| G8430 | Documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an acute health crisis where time is of the essence and delay of treatment would jeopardize the patient's health status) | 0% | 31 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 67 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 18 | $0.00 |
| 36416 | 0% | 41 | $0.00 | |
| 99050 | 0% | 17 | $0.00 | |
| 3079F | 0% | 14 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 1,008 | $0.00 |
| 3078F | 0% | 249 | $0.00 | |
| 1160F | 0% | 33 | $0.00 | |
| 3077F | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTRONG, JOHN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Greenwich Emergency Medical Service, INC. | Riverside, CT | $1.01M |
| Legacy MD Medical Group INC | El Centro, CA | $395K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.